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Abstract We have proposed a clinical treatment guideline for themanagement of acute, severe asthma and chronic
obstructivepulmonarydisease (COPD) using theprinciplesofevidence-basedmedicine.Thecontentisbaseduponprac-
tical clinical issues in need of consensus. A previous study has shown thatthis particular area is in serious need of quality
control.Based on a strict 2 h time schedule with a unified treatment plan for both asthma and COPD, it is possible to
secure for the patients a well-documentedmedical therapy promoting decision-making and clarification of the patient
withinthis timelimit.A summaryofthe statementsispresentedin a one-page, user-friendly formatinorder to copewith
the clinician’s need of having access to published evidence quickly and easily. Awebsite (www.phanareth.dkor awebsite
provided by Respiratory Medicine) has been established providing regular updates. A strategy for the implementation
and the evaluationprocess hasbeenplanned after the publication ofthis paper.We believe this approachto be an impor-
tant step towards an increase in the qualityof guidelines and also a tool tomake‘‘guidelinewriters’’aware ofthe responsi-
bilityofmaking their recommendationswork.r2002 Publishedby Elsevier Science Ltd
doi:10.1053/rmed.2002.1332, available online at http://www.idealibrary.comon
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There is a wide range of divergent recommendations in
the existing literature on the issue of treating acute ex-
acerbations of asthma and chronic obstructive pulmon-
ary disease (COPD). In many cases, it is not possible to
get answers to practical clinical questions from com-
monly available guidelines, i.e. the handling of the inhala-
tion therapy, the doses, and the frequency ofmedication,
oxygen therapy, etc., and the recommendations may dif-
fer widely (1^3).Concerns have been raised about the ef-
¢cacy and validity of guidelines and the impartiality of
consensus statements has also been questioned, as has
their ability to improve clinical practice. In a paper byReceived 5 March 2002, accepted in revised form 6 March 2002.
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Snogeg@rdsvej 99, 2820 Gentofte,Denmark.
E-mail: phanareth@dadlnet.dkGibson, 21 asthma management guidelines were re-
viewed and major de¢ciencies with the assembly of
evidence were found. The author concluded that
recommendations should be based onunbiasedmethods
to obtain the evidence and that a systematical evaluation
and a grading of this evidence should be included in the
publication (4).
The appearance of recommendations based on se-
lected principles of evidence-based medicine (EBM),
showing the grade of the strength of evidence in each
statement, represents a new generation of guidelines
(5^7).The approach is still at a premature stage but de¢-
nitely a step in the right direction. There are, however,
further issues, as pointed out in the EBM, to be taken
into consideration; the process of the documentation
concerning the need for a speci¢c guideline, the formula-
tion of clinical problems, the development of a user-
friendly presentation, how to implement, and, ¢nally,
how to evaluate the impact of the guideline (8,9).
660 RESPIRATORYMEDICINEPreviously, we have shown that a noticeable variation
was found in the management procedures of Danish
Hospitals treating patientswith exacerbations of asthma
and COPD, and that the treatment behavior was only
moderately a¡ected by a national publication of recom-
mendations for the treatment (10). The knowledge we
gained from these studies provided us with useful infor-
mation on clinical problems making it possible to point
out areas in need of quality control. As an obvious con-
sequence, we have proposed a clinical guideline designed
to cover practical issues on the initial treatment of acute
severe asthma and COPD (ASAC)making use of further
principles of EBM.
METHODS
We used modi¢ed components based upon the princi-
ples of EBM (8) as a template in the developmentprocess
of the guideline.The components are shown below:
a. Evaluate the need for a speci¢c guideline.
b. Formulate the problems and questions raised by
clinicians encountering the patients.
c. Search the literature for clinically relevant studies/
papers (the evidence).
d. Evaluate the evidence for its validity and usefulness.
e. Make a clear presentation and layout of the guideline.
f. Implement the guideline.
g. Evaluate the guideline.
Based on the experience gathered from the study of
treatment behaviors in Danish Hospital settings, we
documented a need for a speci¢c clinical treatment
guideline on ASAC.Furthermore, the study provided in-
formation on seven key clinical issues, whichwere as fol-
lows:
1. Inhalation therapy (handling, dosages, etc.).
2. Oxygen treatment (dosages and frequency).
3. Beta2-agonists (route of administration, dosages and
frequency).
4. Anticholinergics (single therapy, combination therapy,
dosages and frequency).
5. Corticosteroids (route of administration, dosages and
frequency).
6. Methylxanthines (yes or no).
7. The strategy.
Literature search was conducted on each item for
both asthma and COPD in Medline and in Cochrane re-
viewsFno studies on infantswere considered.Primarily,
we searched for meta-analyses and randomized clinical
trials (RCTs) butwhen thiswas notpossiblewe searched
well-designed controlled studieswithoutrandomization,
descriptive studies and ¢nally, expert committee re-
ports. Furthermore, if possible, we searched evidence-
based statements in national and internationalguidelines.The authors examined the evidence and the develop-
ment of the recommendations was made in agreement.
The levels of evidence are assigned to statements, where
appropriate, using the grading criteria proposed by the
NHLBI as shown inTable1.Further information are avail-
able from the NHLBI website: http://www.nhlbi.nih.gov/
guidelines/obesity/e_txtbk/appndx/apndx1a1.htm.
Thegradingof the evidence (evidence categoryA, B,C
or D) for each statement is marked in a bracket in the
title of the items separately for asthma and COPD.
A one-page user-friendly summary has further been
developed in accordancewith EBM (11).
INHALATIONTHERAPY
Nebulizers andmetered-dose inhalerswith
holding chambers are equally e¡ective for
inhalation therapy (asthma; grade A,COPD;
grade A)
Bronchodilatory drugs used in the treatment of severe
exacerbations of asthma and COPD should be managed
by inhalation according to the majority of o⁄cial guide-
lines (6,7,12,13). However, the choice of either nebulizers
or metered-dose inhalers with holding chambers (MDI/
HC) for the delivery of inhaledmedication is often based
on tradition. In Denmark, all hospitals use a nebulizer
when treatingpatientswith ASAC although alternatives,
even cheaper and easier to use, might be possible. In a
Cochrane review by Cates et al. including seven studies
on adults with asthma, it was concluded that MDI/HC
produced outcomes that were at least equivalent to
nebulizer delivery (14).
In COPD, a review on six RCTs concluded that the evi-
dence was insu⁄cient to determine that one method of
delivery was superior to the other (7). A meta-analysis
of bronchodilators delivery devices by Turner et al. has
con¢rmed these ¢ndings in patients with acute air£ow
obstruction caused by asthma or COPD (15).
The MDI/HC is considered to be more e⁄cient in
comparing drug doses mg to mg, and the equivalence of
dosesmaybe from2 to12 timesgreater for thenebulized
delivery to achieve the same e¡ect as theMDI/HC (16). In
themeta-analysis byTurneretal., a relativepotencyof 6:1
in favor of MDI/HC compared to the nebuliser was con-
sidered as equivalent (15).
Comment
Werecommend theuse of either nebulizers ormetered-
dose inhalers with holding chamber when treating pa-
tientswithASAC.To achieve equivalent bronchodilation,
the ratio of the dose for a nebulizer compared to MDI/
HC should be approximately 6:1.
TABLE 1. Evidence categories
Evidence category Sources of evidencea De¢nition
A Randomized controlled trials (rich bodyof data) Evidence is from endpoints of well-designed RCTs
(or trials thatdepartonlyminimally fromrandomi-
zation) thatprovide a consistentpattern of ¢ndings
inthe population forwhichtherecommendation is
made.Category A, therefore requires substantial
numbers of studies involving substantial numbers
of participants
B Randomized controlled trials (limitedbodyof data) Evidence is from endpoints of intervention studies
thatincludeonlyalimitednumberof RCTs, post hoc
or sub-group analysis of RCTs, ormeta-analysis of
RCTs. In general, Category B pertains when few
randomized trials exist, they are small in size, and
the trial results are somewhat inconsistent, or the
trials were undertaken in a population that di¡ers
fromthetargetpopulationoftherecommendation
C Nonrandomized trials observational studies Evidence is fromoutcomes of uncontrolled or non-
randomized trials or fromobservational studies
D Panel Consensus Judgment Expertjudgmentisbasedonthepanel’s synthesisof
evidence fromexperimentalresearch described in
theliterature and/orderived fromtheconsensusof
panel members based on clinical experience or
knowledge that does not meet the above-listed
criteria.This category is used only in cases where
the provision of some guidance was deemed valu-
able but an adequatelycompellingclinicalliterature
addressing the subjectoftherecommendationwas
deemed insu⁄cient to justify placement in one of
the othercategories (A^C)
aDescriptionof levels of evidence.Agrading systemdevelopedbyNHLBI fromthewebsitehttp://www.nhlbi.nih.gov/guide-
lines/obesity/e_txtbk/appndx/apndx1a1.htm.
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COPD; grade B)
Nebulizer performance depends on several factors
and anymishandling of the device may have serious con-
sequences for the patients. Consequently, the British
Thoracic Society has published an evidence-based
guideline on Nebulizer therapy with detailed informa-
tion on the handling of the device (5).The statements be-
low are based upon recommendations from the BTS
guideline on Nebulizer therapy and should be
taught carefully to all health-care personnel using
Nebulizers.
K Use air as driving gas for the Nebulizer with a
simultaneous appliance of oxygen by nasal prong or
catheter. Use oxygen as driving gas if medical air is
not available. Do not use small portable
compressors in the emergency room. They needregular £ow calibrations and the reliability is not
well documented.
K Use a ¢ll volume of 4ml if the residual volume of the
Nebulizer exceeds 1.0ml. If the residual volume is
o1.0ml, a ¢ll volume of 2.0^2.5mlmaybe adequate.
K Use a £ow rate of 6^8 lmin1.
K Nebulization time should beo10min.
OXYGENTREATMENT
Use oxygenwhen treating acute
exacerbations (asthma; grade; B,COPD;
grade B)
The administration of oxygen is mandatory in the treat-
ment of patients with acute, severe asthma (12,13). The
aim of the strategy is to provide a continuous arterial
oxygen saturation (SaO2) aiming at a ¢xed SaO2X90%
662 RESPIRATORYMEDICINEto prevent tissue hypoxia.There is little danger of preci-
pitating hypercapnia when administrating oxygen in
acute asthma, even in high doses (13).We could not ¢nd
any RCTs of oxygen in acute asthma, and recommenda-
tions are mainly based on clinical experience and patho-
physiology suggesting its vital role in severe asthma.
The bene¢t of oxygen therapy in exacerbations of
COPD is de¢nitely agreed upon o⁄cial guidelines (6,7).
However, concern has been raised by the fact that oxy-
gen administration can inducehypercarbia bydiminishing
the respiratory drive leading to CO2-narcosis with sub-
sequentrespiratory arrest in somepatients. In a studyby
Gunawardena et al., only a slight increase in pCO2 was
seen in COPD patients with ‘‘pre-treatment’’ hypercap-
nia receiving inhaled beta-agonists by a nebulizer driven
by 8 l of oxygen for 15min.The level of pCO2 fell to nor-
mal values within 20min after the termination of the
nebulization (17).
Agusti et al. performed a study including18 COPD pa-
tients with acute respiratory failure. Patients were trea-
ted with liberal doses of oxygen with the goal of
maintaining a saturation X90%. The strategy did not
worsen the respiratory acidosis signi¢cantly and none of
the patients developed CO2-narcosis (18). Similar ¢nd-
ings have been reported in a recent published study on
24 consecutive patients admitted to hospital with acute
exacerbations associated with hypercapnic respiratory
failure. Oxygen was adjusted every 20min to maintain
an oxygen saturation of 91^92% in the ¢rst 2h of admit-
tance. It was concluded that the risk of CO2 retention
with ‘‘controlled’’ oxygen therapy was low (19). In a huge
summary of published evidence on the exacerbations of
COPD, it was concluded that oxygen administration in
acute exacerbations may result in hypercarbia but that
the patients at highest risk for respiratory failure could
be identi¢ed (7). Guided by the formula proposed by
Bone et al.: pH = 7.660.00919 (PaO2), high-risk patients
can be identi¢ed with a sensitivity of 77% (20). By intro-
ducing the observed PaO2 into the equation, the pH cal-
culated can be compared to the measured pH. In high-
risk patients, the calculated value will be greater than
the measured one indicating caution and special atten-
tion to be taken.
Comment
Severe hypoxemia is often seen in COPD patients with
acute exacerbations and oxygen therapymay be life sav-
ing. It seems rational trying to prevent irreversible tissue
damage induced by hypoxemia by the administration of
oxygen rather than treating potential reversible CO2-
narcosis by oxygen restriction. We believe, guided by
careful clinical observation andby using the simple equa-
tion mentioned above to identify the risk-patients, that
oxygen can be administered bene¢cially and relativelysafely, even in high doses. If, however, the patient’s hyper-
capnia becomes increasingly worse under the oxygen
treatment and signs of CO2-narcosis develop, then a gra-
dual reduction in oxygen is recommended instead of a
sudden withdrawal leaving the patient in severe hypoxe-
mia.
In the proposed guideline, it is recommended to use
3^5 lmin1oxygen during the ¢rst hours of admittance-
Faiming at keeping the saturationX90% regardless of
whether the patients su¡er from asthma or COPD. It
must be emphasized that oxygen administration should
be continued during the nebulizer therapy if the nebuli-
zer is driven by air.
In the second hour of the treatment, a further indivi-
dualization may be possible due to the monitoring pro-
cess revealing more detailed information on the
patient’s status. As a consequence, we recommend the
use of1^5 lmin1oxygenduring the secondhourof treat-
ment. This is, in fact, in accordance with the American
Thoracic Society guideline (21).
BETA2-AGONISTS
Route of administrationFinhalation equal
to orbetter than intravenous administration
(asthma; grade A,COPD; grade C)
Inhaled beta2-agonists is recommended as a ¢rst-line
therapy by the o⁄cial guidelines and is regarded as the
most potent reliever of bronchospasm in acute asthma
and COPD (6,7,12,13).
In a recently completed Cochrane review, 15 RCTs
were included to determine the bene¢t of intravenous
beta2-agonists in severe acute asthma compared to
other regimes (inhaledbeta2-agonists). It was concluded
that the medical literature did not provide any compel-
ling reason to favor intravenous administration to in-
haled beta2-agonist therapy (22). There are, to our
knowledge, no studies of acceptable quality covering this
issue in COPD.
Comment
We do notrecommend theuse of infusedbeta2-agonists
in acute exacerbation of asthma and COPD. Bronchodi-
lator therapy should be given by the route of inhalation
when using both beta2-agonists and ipratropium bro-
mide.However, the intravenousroutemaybe considered
as a supplement for patients in need ofmechanical venti-
lation and in the casewhere no other treatment options
have been e¡ective.
Potency of beta-agonists (grading; C)
Terbutaline, salbutamol, and fenoterol are the most fre-
quently used beta2-agonists in ASAC. They di¡er in
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has been investigated in several studies, mostly on stable
patients, and it seems agreed upon among authors that
the relation between potencies are: fenoterol/salbuta-
mol/terbutaline:1:2:3, fenoterol being the most equally
potent (23,24).This relation has been adapted in the pro-
posedrecommendation and is in accordancewith several
o⁄cial guidelines (6,12,25^27).
Continuous nebulization equal to
intermittent (asthma; grade A,COPD;
grade C)
Continuous nebulization has been claimed by several
specialists to be superior to intermittent nebulization.
A review of eight RCTs comparing continuous vs inter-
mittent administration of bronchodilators in acute asth-
ma showedboth regimes to be e¡ective butwith a small
bene¢t from using continuous nebulization, especially in
severe cases (28).
We found no studies on COPD covering this issue.
Comment
In the perspective that continuous nebulization does not
seem to induce increased side-e¡ects (29), that it might
have a bene¢cial e¡ect on severe exacerbation, and that
it reduces the amount of sta¡ time required (30), wewill
recommend continuous nebulization as an alternative to
intermittent nebulization (if technical equipment allows
it) in the treatment of severe exacerbations of asthma
and COPD.
Dose and frequency (asthma; grade A,
COPD; grade B)
The optimal dose and frequency of the administration
of inhaled beta2-agonists are not fully clari¢ed. At
least two well-designed studies on asthma have sup-
ported the use of small doses with a frequent interval
showing that inhalations of 2.5mg salbutamol with
20min interval were optimal in the ¢rst hours of in-pa-
tient treatment in hospitals (31,32). The study by
McFadden et al. has con¢rmed the bene¢ts from this
strategy (33).
Few studies cover the issue in COPD. A dosing study
by Emermann and colleagues including 86 patients with
COPD failed to show any di¡erence in FEV1 on compar-
ing patients who received 2.5mg nebulized albuterol
every 20min with those who received it every hour.
However, it was suggested that severely obstructed pa-
tients (FEV1o20%predictednormal)mayhavebene¢ted
from the ¢rst regime (34).Comment
Additional studies are required to determine the optimal
dosing in both asthma and COPD. However, based on
the above studies, we believe 2.5mg of salbutamol (or
equivalent drug) administered at 20-min intervals by
nebulizer, at present, to be the best recommendation in
treating acute exacerbations of both asthma and COPD.
This is, in asthma, in accordancewith theNHLBguideline
(27) and in COPDwith the BTS guidelines (26).
When using continuous nebulization, the doses of
beta2-agonist must equal the recommended doses for
intermittent therapy (i.e. cumulative dose of 2.5mg sal-
butamol every 20min used in intermittent nebulization
equals a dose of 7.5mg used hourly for continuous nebu-
lization).
ANTICHOLINERGICS
Make use of combination therapy (asthma;
grade A,COPD; grade B)
Combination therapy with inhaled beta-agonists and an
anticholinergic agent is well documented in asthma.The
rationale of adding nebulised ipratropium bromide (IPB)
is the presence of increased airway vagal tone, which
may not be overcome by treatment with high doses of
inhaled beta2-agonists alone (35).
Two separate meta-analyses have shown signi¢cant
bene¢ts on FEV1, peak expiratory £ow (PEF) and admis-
sion rates when adding IPB to a beta-agonist in acute
asthma (36,37).
In COPD, the evidence concerning the e¡ectiveness of
combination therapy is con£icting.We found four RCTs
in COPD showing no di¡erence in lung function para-
meters comparing combination therapy to single ther-
apy using a beta2-agonist (38^41). In contrast, we found
three RCTswhichwere able to showbene¢ts from com-
bination therapy in the lung function parameters (42^
44).
Comment
In the perspective that the proposed guideline uni¢es
the treatmentof asthma andCOPD and that the toxicity
and the side-e¡ects from IPB isminimal (7,30,45), combi-
nation therapy is recommended for bothdiseases in spite
of the fact that the evidence of this strategy in COPD is
rather controversial.
Dose and frequency (asthma and COPD:
grade B)
From the meta-analysis by Rodrigo et al., in asthma, the
average dose of IPB used in the pooled RCTs was be-
tween 0.5 and1.5mgduring the ¢rst 2h of the treatment
664 RESPIRATORYMEDICINE(36). In the seven RCTs found in COPD (mentioned
above) the doses of IPB ranged from 0.04 to 2mg within
the ¢rst hour of treatment.The optimal dose of IPB can-
not be clari¢ed from the existing literature neither in
asthma nor in COPD.
Comment
The studies on asthma and COPD reviewed in this sec-
tion have used additional doses of IPB ranging from 0.04
to 2.0mg.There is no evidence in asthma to support the
use of higher doses than 1.5mg during the ¢rst 2h of
treatment in the acute settings. In COPD, though insu⁄-
ciently supported by evidence, up to 2.0mg given in the
¢rst hoursmay provide some additional bene¢t (42).
Since our proposal uni¢es the treatment strategy for
both asthma and COPD,we ¢nd it reasonable to recom-
mend the use of a cumulative dose of 2.0mg IPB, well
aware that the recommended dose might be slightly
higher thanmaybe supportedby the evidence.However,
we do not ¢nd this hazardous since the systemic
side-e¡ects of IPB are believed to be almost negligible
(46) and the fact that the optimal dose yet needs to be
investigated, may further justify this recommendation.
By using combination therapy with a dose of 0.5mg
IPB and 2.5mg of salbutamol (or equivalent drug) given
in 20-min intervals during the ¢rst hour (at time 0, 20,
40 and 60-min) the recommended dose is reached.
Thus, if bronchodilator treatment is to be continued
during the second hour, a switch to monotherapy
using 2.5mgof salbutamol (or equivalentdrug) is recom-
mended.
CORTICOSTEROIDS
Corticosteroids should be used in the
treatment of acute exacerbations (asthma;
grade A,COPD; grade A)
The bene¢t of treating patients with acute asthma with
systemic corticosteroids has been documented in a Co-
chrane review including12 RCTs involving 863 patients. A
signi¢cant reduction in hospital admissions was achieved
by the administration of corticosteroids (intravenous or
orally) within an hour of the presentation to the emer-
gency department (47).
In COPD we found ¢ve RCTs comparing the e¡ect of
corticosteroids to placebo (48^52).The study by Albert
et al., including 44 in-patients showed better improve-
ment of FEV1 in patients treated with corticosteroid
compared to placebo (49).However, the statisticalmeth-
ods and analyses in Albert’s study have been seriously
questioned leaving the evidence from this study unclear
(53). Another studybyThompson etal. from1996 showed
accelerated recovery in 13 out-patients receiving oralprednisolone measured by lung function parameters,
blood gases and dyspnea score comparedwith the14 pa-
tients in the placebo group (48). However, taking the
small sample and the patient population (out-patients) in
to account, no consistent conclusions can be made. A
study by Emerman et al. could not show any e¡ect of
100mg methylprednisolone compared to placebo in 96
patients with acute exacerbation of COPD (51). Davies
and colleagues randomized 56 COPD patients admitted
with severe exacerbation to receive either low-dose cor-
ticosteroid (30mg oral prednisolone) or identical place-
bo for14 days. Signi¢cant improvements in lung function
and shortening of length of hospital stay were associated
with the use of corticosteroids.Unfortunately, informa-
tion on the acute e¡ect (within a few hours of the pre-
sentation to the ER) cannotbe clearly extrapolated since
the protocol was started within 3h of the presentation
in the emergencyroomandbecause themeasurementof
the ¢rst treatment responses was done after 24h (52).
The largest study has been performed by Niewoehner
et al. including 271patients with COPD admitted to hos-
pitalwith acute exacerbation.Patientswere randomized
in three groups; two active groups initially treated
with the same doses of intravenous corticosteroids
(125mg methylprednisolone every 6h for 3 days) fol-
lowed by di¡erent regimes of tapering o¡ oral predniso-
lone and one placebo group. Moderate bene¢ts were
detected in the ¢rst 8 weeks in the two active groups
compared to placebo but no di¡erence was found at a
follow-up after 6 months. The protocol was activated
within12h of thepresentation of thepatient in the emer-
gency room with the ¢rst measurement of response
after 24h of entering the study. Neither does this study
provide any conclusive information on the acute e¡ect of
corticosteroids (50).
Comment
There is solid evidence to support theuse of corticoster-
oids in acute asthma and the drug should be adminis-
tered as early as possible upon the arrival of the patient.
In exacerbations of COPD, there is substantial evi-
dence to promote the use of a short course of systemic
corticosteroids. However, the e¡ect within the ¢rst
hours of treatment has not been investigated but the lit-
erature supports a bene¢cial e¡ectdetectable after 24h.
It is, however, not clear when to initiate the treatment
with corticosteroids.Data suggest that commencement
within12h of presentation in the emergencydepartment
to be su⁄cient.
Consequently, we recommend the use of systemic
corticosteroids in both diseases administered upon arri-
val of the patient. The fast commencement directed by
the evidence on asthma advocating an initiation as early
as possible.
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administration (asthma; grade A,COPD;
grade A)
The equal bene¢t of orally and intravenously adminis-
tered corticosteroids in severe conditions of asthma has
been well documented (47,54,55). In a Cochrane review
by Rowe et al. there was no evidence to suggest that
one route improved outcomesmore than the other.
In COPD, the pattern is similarly veri¢ed in a meta-
analysis by Wood-Baker et al., showing no di¡erence be-
tween the two routes of administration (56).
Comment
The evidence supports the use of both administration
forms as options. However, we will recommend the use
of intravenous administration of corticosteroidsFonly
to re£ect the importance of having an intravenous access
to the patient as a precaution.
Dose and frequency (asthma; grade A,
COPD; grade A)
A Cochrane review by Manser et al. has recently been
published to determine whether higher doses of oral/in-
travenous corticosteroids aremore e¡ective than lower
doses in the management of acute asthma. Measure-
ments of FEV1, respiratory failures, and side-e¡ects
showed no di¡erence in a follow-up period of 24h when
comparing methylprednisolone equivalents in low (r =
80mg) vs medium (480mg and r = 360mg) vs high
dose (4360mg) (55). In a meta-analysis by Rowe et al.,
it was suggested that doses ofo30mg in the ¢rst 24h
were sub-optimal (54).
ACochrane reviewby Wood-Bakeret al. based on se-
ven RCTs on exacerbations of COPD compared doses
between 25 and 160mg of methylprednisolone in the
¢rst 24h to placebo. No convincing e¡ect on the mea-
sured outcomes could be detected evenwhen using high
doses (56).However, in the study byNiewoehner et al., a
signi¢cant improvement in FEV1was seen in the corticos-
teroid-group after 24h using125 mg every 6h (50).
Comment
The optimal dose of corticosteroid used in treating ex-
acerbations is still unclear in both asthma and COPD.
However, there is evidence to support that a dose ran-
ging from 30 to ^ 400 mg ofmethylprednisolone should
be used initially in asthma with no concern of side-ef-
fects. In COPD, the strongest evidence is found in Nie-
woehner’s study suggesting 125 mg to be the initial
dose. As our proposed guideline covers both diseases,
we have, in this case, chosen COPD as the determinantand recommend a dose of120 mg of methylprednisolone
to be usedFwell aware that this dose might be supra-
optimal for asthma.
Inhaled corticosteroids (no grading)
Theuse of inhaled corticosteroids in acute exacerbations
of asthma and COPD are controversial. However, Ed-
mons et al. havepublished a Cochrane reviewon the sub-
ject in asthma (57). The authors could not ¢nd a clear
bene¢tof inhaled corticosteroids (ICS) in addition to sys-
temic corticosteroids neither could they show ICS alone
as e¡ective as intravenous administration. There are no
studies, to our knowledge, covering this aspect in
COPD.
The proposed guideline does not recommend the use
of inhaled corticosteroids.
METHYLXANTHINES
Donot usemethylxanthines in acute
exacerbations (asthma; grade A,COPD;
grade C)
There are con£icting messages concerning the use of
methylxanthines in acute asthma when looking at re-
commendations from guidelines (1,3,13,27). However, the
evidence is quite clear on thismatter. Ameta-analysis by
Littenberg could not detect any bene¢ts from adding
methylxanthines to beta-agonists in acute asthma (58).
This has recently been supported in a published Co-
chrane review by Parameswaran et al., where no addi-
tional e¡ect to standard care with beta-agonists was
found. In fact, the frequency of adverse e¡ects was high-
er with aminophylline (59).
In exacerbations of COPD the evidence is still unclear.
In a summary of the evidence on acute management of
COPD, three RCTs were found comparing methyl-
xanthines as add-on therapy to ‘‘standard therapy’’ (in-
cluding short-acting beta2-agonists). No di¡erence
between lung function parameters could be found
though one studycouldreport a trend towards lower ad-
mission rates in the aminophylline group. However, the
frequency of adverse events was higher with theophyl-
line (7).
Comment
There is no evidence to support additional bene¢t from
the use ofmethylxanthines.Combinedwith the fact that
the drughas substantial side-e¡ects and a narrow thera-
peutic index, the use of methylxanthines is not recom-
mended in the proposed guideline, neither in COPD nor
in asthma.
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Use a pre-determined treatment schedule
(asthma; grade B,COPD; grade C)
The treatment of acute exacerbations in an emergency
setting is a multi-disciplinary task and the potential life-
threatening situation demands immediate handling with
prompt initiation of a multiple drug therapy. Conse-
quently, it seems reasonable to adapt a certain treat-
ment strategy and to have predetermined schedules for
both nursing sta¡ and physicians.
In a well-designed, controlled study by McFadden and
co-workers, it was shown that a pre-determined man-
agement plan in asthma had a signi¢cant impact on the
length of the stay in the emergency room, admissions,
re-admissions and ¢nancial savings compared to ‘‘usual
care’’ (33). Schnider et al. have con¢rmed similar ¢ndings
(60).We couldnot ¢nd any studies in COPD covering the
issue.
Comment
We have adapted the strategy used by McFadden and
colleagues in the proposed guideline primarily based on
an aggressive use of sympathomimetics, oxygen and cor-
ticosteroids in association with serial monitoring of key
indices of improvement needed for a rational decision-
making. The guideline is based on a strict management
plan covering the initial 2 h of the treatment in the emer-
gency roommaking no distinction between asthma and
COPD (Fig.1). We believe a prompt commencement of
therapy to be better than delaying the treatment due to
di¡erential diagnostic considerations. Upon arrival, the
patient is immidiately suppliedwith oxygen by a nasal ca-
theter or a nasal prong (3^5 lmin1) continuously
throughout the ¢rst hour. All patients undergo an initial
monitoring of the parameters listed in Fig.1 (key indices).
These parameters constitute the foundation for a later
‘‘decisionsmaking’’.
Simultaneously, thepatientreceives intravenous corti-
costeroids and nebulized beta2-agonist in combination
with ipratropium bromide as described in Fig.1. (t =
0min). The inhalation therapy is repeated every 20min
and the oxygen supply should be continued during the
process.
The ¢rst evaluation of ‘‘treatmentresponse (1)’’ is per-
formed after 60min by repeating the measurements of
the ‘‘key indices’’ done initially. Hereby, a comparison can
be performed serving as a foundation for the ¢rst ‘‘deci-
sionsmaking’’:
1. Has the patient’s condition worsened and is the
patient in need of intensive care?
2. Has the patient’smonitoring parameters improved to
such a degree that discharge is possible?3. Is the condition of the patient unchanged or is it
di⁄cult to make a decision at this moment? If so, the
patient is treated and observed for another hour in
the emergency department.
If the patient’s condition remains unchanged or show-
ing small progress, the treatmentcontinues in the ER fol-
lowing the same strategy as in the ¢rst hour. However,
combination therapy using IPB in combination with a
beta2-agonist is switched to monotherapy using a
beta2-agonist alone in the next hour and the oxygen
therapymight be further individualized.
The second treatmentresponse (‘‘treatmentresponse
2’’) is performed after 2h to enhance the ¢nal decision-
making whether the patient should be discharged, ad-
mitted or referred to intensive care. As a consequence,
patients are clari¢edwithin 2h. In severe cases, itwill be
necessary to monitor treatment response more fre-
quently (i.e. every 30min) but as a standard, an hourly
monitoring seems appropriate.
Relevant signs of deterioration have been listed in the
guideline speci¢ed for asthma andCOPD as proposedby
the GINA-guidelines (12) and the GOLD-guidelines (6)
and should bemonitored regularly to assess the severity
and to act upon if deterioration occurs. Further, the dis-
charge criteria from the sameguidelineshavebeen listed.
There is no available grading of the evidence on these
statements.
By means of this strategy, we believe patients are se-
cured a su⁄cient baseline treatment satisfying the qual-
ity demands of a modern acute setting. Regular training
of doctors and nurses and a close teamwork between
the emergency sta¡ are mandatory adapting this man-
agement strategy. However, the results could be a ra-
tional and e¡ective course giving patients a treatment
which is uni¢ed, su⁄cient andwell documented.
Other treatments anddiagnostics
Antibiotics
The use of antibiotics in acute exacerbations is contro-
versial in both asthma and COPD. A Cochrane review
by Graham et al. found two RCTs including 97 patients
with acute asthmabutcouldnot ¢nd any substantial ben-
e¢ts comparing the use of antibiotics to placebo (61).
In COPD, a review on the basis of 11 RCTs concluded
that antibiotics are e¡ective in the treatment of patients
with acute exacerbations of COPD. However, many of
the studies were performed before the emergence of
pathogens that are resistant to multiple antibiotics (7).
The GOLD-guideline claims antibiotics to be e¡ective
only in patients with worsening dyspnea and cough also
having increased sputumvolume and purulence (6).
We do not ¢nd the evidence of the use of antibiotics
neither in asthma nor in COPD and, therefore, do not
FIG. 1. Summaryoftreatmentguideline (full-size format).
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the symptoms mentioned above con¢rmed by (or sus-
pected because of) in¢ltrates on the chest
X-ray, a treatmentwith antibiotics shouldbe established.
The choice of agents should, of course, be in accordance
with local patterns of antibiotic sensitivity among
pathogens.
Sedatives
The use of sedatives in the treatment of acute exacerba-
tions of asthma and COPD is controversial and is not re-
commended in our treatment schedule. If, however,
anxiolytics are to be used, drugs producing a minimum
ofrespiratorydepression arerecommended (i.e. levome-
promazine).
Chest X-rays and others
Chest radiography is a useful test in identifying alterna-
tive diagnosis and possible infections (6,7,13) and should
be performedwithin the ¢rst hours without delaying or
interfering with the treatment schedule.
The collection of blood samples with the measure-
mentof plasma electrolyte, blood count,C-reactive pro-
tein and urea concentrations should be regarded as a
standard procedure in the acute settings.
DISCUSSION
We have proposed a guideline focusing on practical clin-
ical issues treating patients with acute, severe asthma
and COPD in an emergency setting. The presented re-
commendation is designed to cover the initial 2 h of a
treatment strategy securing a well-documented, stan-
dardized treatment and promoting decision-making and
clari¢cation of the patient within this time limit. Since
the treatment of acute exacerbations for asthma and
COPD is based on the same therapeutic principles, we
haveproposed a uni¢edmedical treatment in the recom-
mendation. Consequently, some minor compromises
have been necessary resulting in a tendency towards an
‘‘over-use’’ofmedication in accordancewith the evidence.
However,we are dealingwith a potential life-threatening
disease justifying ‘‘over-treatment’’ rather than ‘‘under-
treatment’’.
Though many clinical signs are similar in asthma and
COPD upon presentation in the emergency settings,
there are di¡erences in the para-clinical ¢ndings and in
the signs used to evaluate deteriorations and improve-
ments.Therefore, it has been necessary to discriminate
between these indicatorsusingdi¡erentcriteria for asth-
ma and COPD as illustrated in the scattered blocks on
both sides of the recommendation (Figs. 1 and 2).Thereare disadvantages using a pre-determined treatment
plan with a rigid therapeutic regime and precautions are
needed: extremely ill patients with severe respiratory
failure should be transferred immediately without delay
to the intensive care unit and on the other hand, milder
cases may be dragged through unnecessary medical ap-
proaches. It must be emphasized that this recommenda-
tion does not deprive the respiratory sta¡ of their usual
responsibility and care for the patients nor does it ex-
emptdoctors fromusing their clinical skills and‘‘common
sense’’. However, we believe this recommendation to be
useful as a tool in managing the vastmajority of patients
presenting with severe exacerbations and should be re-
garded as a support for a rational therapeutic approach
giving strength to the diagnostics, the quality of the
treatment, and the decision-making.
Essential parts of the EBM have been used creating
this guideline. We have documented a need for quality
control and a need for a speci¢c clinical recommendation
treating acute, severe exacerbations inDanish acute, set-
tings (10). Aspointedout in the EBM,wehave formulated
problems and targeted severalkey clinical issues to be in-
vestigated (62).The evidencewas appraisedby a group of
four clinicians and recommendations were made in
agreement.We are well aware that this is not fully in ac-
cordance with the EBM calling on multi-disciplinary ex-
pert panels as a correct methodologic approach (9).
This may have introduced certain subjective biases into
theprocess, but even so some advantagesmay havebeen
gained. As no political issue had to be considered, we
were not forced into compromised solutions weakening
the statements and we were not biased by any ¢nancial
in£uence. In fact, this might even have strengthened the
recommendation from a clinical pointof view.Webelieve
EBM to be a tool not only justi¢ed in the hands of expert
panels and specialists but also a tool to be used by any
clinician in doubt of possible aspects of management, di-
agnosis and prognosis (11).
The ambitious task unifying recommendations for
both asthma and COPD has called upon a major review
of published literature in search of evidence and some
studies may have been overlooked. However, the state-
ments (and the grading of statements) are in most cases
based on Cochrane reviews, meta-analysis and well-de-
signed RCTs making us believe our appraisal to be reli-
able. It is, though, important to emphasize that the
guideline should be updated regularly. This should be a
continuous process with updates as new trial data
emerge if the recommendation is to continue to be use-
ful in clinical practice (63). As a consequence, we have
established a web address (www.phanareth.dk) in
which regular updates of the proposed guideline will be
available.
It is crucial for clinical teams, especially the emergency
teams with little time and much information to absorb,
to be capable of accessing published evidence quickly
Assessment Assessment
• A lack of response to 
initial therapy in the 
emergency department 
and/or rapidly worsening 
asthma
•
•
• Intubation may be           
needed  if  there is   
in clinical features 
Signs of deterioration
in asthma:
5 l / min. through nasal catheter between and under 
nebuliser therapy aiming at a fixed saturation of 
Signs of deterioration
in COPD:
•
responds inadequately
to  Initial emergency 
therapy
• Confusion, lethargy, 
coma
• Persistent or worsening 
worsening hypercapnia
Discharge criteria
in asthma :
 PEF > 70% pred.
 Physical examination :
normal
 No distress 
 Saturation > 90%
 Sustained response
> 60 minutes
Discharge criteria
in COPD:
 Beta2-agonist required
no more frequently than
every 4 hrs
 The patient is able to 
walk across the room
 Clinically stable for 12 –
24 hrs 
 Arterial blood gases 
stable for 12 – 24 hrs
 Practical arrangement
solved (medication, 
family home care 
arrangements)
90%
OXYGEN - THERAPY
≥
Repeat initial monitoring parameters and assess  the treatment 
response. Decide weather the patient should be discharged, 
Blood gasses or pulse 
diaphoresis and anxiety.  
INITIAL - MONITORING
oximetry(+ / - oxygen),
Peak - flow (best of three), pulse, blood pressure, 
resp. frequency. Clinical judgement (classify yes / no) :
Cyanosis, use of accessory muscles, ronci, stridor, 
0 min
40 min
60 min
80 min
100 min
120 min
20 min
0 min
20 min
40 min
60 min
80 min
100 min
120 min
Presence of confusion, 
drowsiness, other signs 
of impending respiratory 
arrest, or loss of 
consciousness
Impending respiratory 
arrest : hypoxemia 
despite supplemental 
oxygen (PO2 < 8 kPa ) 
and/or PCO2 > 6 kPa 
(although respiratory 
failure may occur with 
either a high or low 
PCO2) 
continued deterioration 
i  li i l f t  
despite  optimal 
therapy, if the patient is 
exhausted, and / or if the 
PaCO2 is increasing
3 - 5 l / min. through nasal catheter also during the 
nebuliser therapy - aiming at a fixed saturation of ≥90%.
OXYGEN - THERAPY
INHALATION THERAPY 
Repeat combination therapy as above
INHALATION THERAPY 
Repeat combination therapy as above
1 -
Mono therapy with 5 mg terbutaline or 
2,5 mg salbutamol
DISCHARGE
Discharge with course of
oral pednisolone 30-40 mg
daily for 10 days and a 
rasied dose of inhaled 
steroid and broncodilator
Control after one week in a
pulmonary outclinic setting
INTENSIVE
CARE UNIT
Judged by the clinical and
paraclinical signs listed.
TREATMENT RESPONSE (2)
Repeat initial monitoring parameters and assess  the treatment 
response. Decide weather the patient should be discharged, 
transferred to IC unit or admission.  
ADMITTANCE
Severe dyspnoea that  
of hypoxemia  (PaO2 < 
6.7 kPA),and/or severe/        
(PaCO2 > 9.3 kPa) and/ 
or severe/ worsening  
respiratory acidosis 
(pH < 7.3) despite 
supplemental oxygen
A practical clinical treatment guidline for acute severe asthma and COPD 
- an evidence-based management plan covering the first two hours of treatment in the ER -
TREATMENT RESPONSE (1)
transferred to IC-unit or continue treatment in the emergency room.  
Mono therapy with 5 mg terbutaline or 
2,5 mg salbutamol
INHALATION THERAPY 
Mono therapy with 5 mg terbutaline or 
2,5 mg salbutamol
INHALATION THERAPY 
INHALATION THERAPY
nebulisation 
minutes
INHALATION THERAPY
Nebuliser : 5 mg terbutaline or 2.5 mg salbutamol in 
combination with 0.5 mg Ipratropiumbromide
Flow: 6-8 l x min 1, driving gas: air, time:
< 10 , fill volume: 4 ml
pMDI + spacer : Use same drug as for nebulisers but in 
a 6-fold decreased dose 
CORTICOSTEROIDS
120 mg methyl -prednisolone 
Intravenous or150 mg 
prednisolone orally
+
 
FIG. 2. Summaryofthe treatmentguideline inpocketsize format.
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sentation of the guideline,wehave designed theguideline
as a one-page, user-friendly summary using short state-
ments with a clear focus on practical clinical issues
shown in Fig.1 (large-scale format) and in Fig. 2 (pocket-
size format).
At thismoment, theprocess of distribution and imple-
mentation is in progress.The summary of the guideline is
available in di¡erent formats (A4-format, PowerPoint-format, pocket-size format and as a PDF-¢le) download-
able from the homepage: www.phanareth.dk. In relation
to the publication of this paper, the guideline will be dis-
tributed to all Danish hospitals andplans aremade to es-
tablish a parallel publication in the weekly bulletin for
Danish physicians.
We have planned to evaluate the impact of the guide-
line within the next 2 years by use of the methods de-
scribed in the study performedby our team (10).
670 RESPIRATORYMEDICINEConclusion
We have used the principles of EBM in the development
of a practical treatment guideline targeting clinicians
working in the emergency ward treating patients with
acute severe exacerbations of asthma andCOPD.Webe-
lieve this approach to be an important step towards an
increase in the quality of guidelines and also a tool to
make ‘‘guideline writers’’ aware of the responsibility of
making their recommendations work.
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